No difference between Hashimoto's thyroiditis and Graves' disease in the
association of other autoimmune conditions - systematic review and
meta-analysis
Greta Pham-Dobor
Ist Department of Medicine, University of Pécs, Medical School, 13 Ifjúság, Pécs, Szentágothai Research Centre, Pécs, 20 Ifjúság út, Pécs
Corresponding Author:[email protected]
Author ProfilePeter Hegyi
Institute of Translational Medicine, University of Pécs, Medical School, 12 Szigeti, Pécs, Centre for Translational Medicine, Semmelweis University, Budapest, 26 Üllői, Division of Pancreatic Diseases, Heart and vascular Center, Semmelweis University, Budapest, 26 Üllői
Author ProfileKatalin Marta
Centre for Translational Medicine, Semmelweis University, Budapest, 26 Üllői,Division of Pancreatic Diseases, Heart and vascular Center, Semmelweis University, Budapest, 26 Üllői
Author ProfileBalint Eross
Centre for Translational Medicine, Semmelweis University, Budapest, 26 Üllői,Division of Pancreatic Diseases, Heart and vascular Center, Semmelweis University, Budapest, 26 Üllői
Author ProfileAbstract
Objective: In autoimmune polyglandular syndromes (APS) both types of
Autoimmune Thyroid Disorders (AITDs), i.e. Hashimoto’s thyroiditis (HT)
and Graves’ disease (GD) can be present. Design: In this meta-analysis,
we aimed to provide the first comprehensive overview of the differences
between HT and GD in APS II and III. Methods: Using the MEDLINE and
Embase databases all studies containing the keywords of APS II and APS
III were screened. Out of 479 studies 18 records containing a total of
1312 patients fulfilled the criteria of our study and were selected for
analysis. Meta-analysis was performed using the random-effects model.
Results of each meta-analysis were displayed graphically using forest
plots. Results: AITDs were detected in 87.8% of APS patients. HT and GD
were specified in 279 and 151 cases, respectively. In the remaining 309
cases, the diagnosis was AITD, without any further characterization. The
prevalence of HT, GD and AITD did not differ among APS patients. The
pattern of co-associated endocrine, non-endocrine organ-specific and
systemic autoimmune disorders was similar in HT and GD. T1DM and AD were
found in larger proportion of patients, 70.7% and 18.5%, respectively.
Other autoimmune conditions occurred in <4%. The majority of
autoimmunities occurred in dual combinations (91.8%). The combination
of four and more autoimmune disorders was published only in HT, in 0.1%
of patients. Conclusions: Using a meta-analysis, no difference could be
observed in the prevalence of HT and GD among APS patients and no
distinct pattern of co-associated autoimmunities could be established.